CPT 17000 and 17004 Actinic Keratosis Destruction Documentation for Immunosuppressed Transplant Patients After Failed Field Therapy

CPT 17000 reports destruction of the first actinic keratosis, 17003 reports lesions two through fourteen, and 17004 alone reports fifteen or more. For immunosuppressed transplant recipients who failed field therapy, documentation must link an exact lesion count, L57.0, Z79.6 subcodes, transplant status, and dated field therapy failure.

This playbook is written for clinic medical directors who oversee dermatology, transplant dermatology, or multispecialty practices that destroy premalignant lesions in solid organ transplant recipients (SOTRs). It covers code selection, diagnosis sequencing, field therapy failure documentation, Modifier 25 defensibility, same-day procedure conflicts, and a monthly audit protocol. Each section is built to be copied directly into internal compliance policy.

Exact lesion counts determine whether 17000, 17003, or 17004 is billable

The 17000 series is count-driven. Size, method, and anatomic site do not change the code. Only the total number of premalignant lesions destroyed during the session matters. A note that says "multiple AKs treated with LN2" cannot support any unit count beyond one, and in a post-payment review it may not support 17000 at all.

The code ladder for premalignant lesion destruction

• 17000, first lesion only: Reported once per date of service, regardless of how many anatomic sites are treated.

• 17003, lesions 2 through 14: Add-on code reported per lesion with 17000, up to 13 units (the Medicare MUE is 13).

• 17004, 15 or more lesions: Reported as a single unit and never combined with 17000 or 17003 on the same date.

The most common billing error occurs at exactly 15 lesions. Coders who stack 17000 plus 14 units of 17003 exceed the MUE and trigger an automatic edit. The correct claim for 15 lesions is 17004 times one. For 14 lesions, the correct claim is 17000 plus 17003 times 13. Fourteen lesions and forty lesions both resolve to a single structural rule, so the note must make the count unambiguous.

Worked examples for coding staff

• One lesion on the scalp: 17000 times 1.

• Nine lesions across face and hands: 17000 times 1, 17003 times 8.

• Fourteen lesions on the dorsal forearms: 17000 times 1, 17003 times 13.

• Twenty-six lesions on scalp, ears, and hands: 17004 times 1.

Count lesions per anatomic site, then sum them in a final reconciled total. Auditors compare the site-level tally with the billed units. When the narrative says "approximately 20" and the claim shows 17004, the word "approximately" becomes the audit finding. Require integers, never ranges or estimates.

Rule: No integer lesion count means no defensible destruction claim.

Transplant immunosuppression converts routine AK destruction into high-risk medical necessity

Solid organ transplant recipients carry a cutaneous squamous cell carcinoma (cSCC) risk that published cohorts place at roughly 65 to 250 times that of the general population. Their SCCs grow faster, recur more often, and metastasize more frequently. Actinic keratoses in this population are best understood as markers of field cancerization in a patient whose immune surveillance has been pharmacologically suppressed.

Medicare coverage is not the obstacle. Under National Coverage Determination 250.4, Medicare covers destruction of actinic keratoses without restriction based on lesion or patient characteristics. Commercial and Medicare Advantage plans are a different matter. Many require documented medical necessity, and some deploy prepayment review on high-volume 17004 claims. The transplant context is the strongest medical necessity argument available, but only if it is coded and documented.

The diagnosis stack that supports medical necessity

• Primary diagnosis, actinic keratosis: L57.0 (ICD-10-CM) linked to every 17000, 17003, and 17004 line.

• Long-term immunosuppressant use: Z79.6 (ICD-10-CM) category, coded to the highest specificity (for example, Z79.621 for calcineurin inhibitors such as tacrolimus, Z79.623 for mTOR inhibitors such as sirolimus, Z79.624 for nucleotide synthesis inhibitors such as mycophenolate).

• Transplant status by organ: Z94.0 (kidney), Z94.1 (heart), Z94.2 (lung), Z94.4 (liver), and related Z94 codes.

• Drug-induced immunodeficiency, when documented: D84.821 with the appropriate adverse effect code (T45.1X5 for immunosuppressive drugs).

• Personal history of skin cancer: Z85.828 when the patient has prior cSCC or other non-melanoma skin cancer.

Z79.6 is a category, not a billable code by itself. Since the FY2024 ICD-10-CM expansion, the category requires additional characters. Submitting a truncated Z79.6 generates a rejection that delays the entire claim. Train coders to pull the medication list into code selection, and require providers to name each immunosuppressive agent in the assessment.

Multi-agent regimens need multiple codes. A kidney recipient on tacrolimus and mycophenolate should carry both Z79.621 and Z79.624. Each code tells the payer something distinct about carcinogenic risk. Azathioprine, for example, carries specific photosensitizing and mutagenic concerns, and calcineurin inhibitors are independently associated with cSCC risk.

Explore specialty-specific coding references in the Specialty Clinical Documentation Library, which includes transplant dermatology diagnosis stacks and organ-specific risk language.

Failed field therapy must be documented as a dated, agent-specific clinical event

Field therapy failure is the clinical bridge between a patient who could be managed topically and a patient who now needs lesion-directed destruction. Payers that scrutinize 17004 frequency in transplant patients often ask a simple question: why destroy individual lesions when field-directed treatment exists? The note must answer that question before the auditor asks it.

Seven elements of a defensible failure record

• Agent and concentration: For example, fluorouracil 5% cream, fluorouracil 0.5% cream, imiquimod 3.75% or 5%, tirbanibulin 1%, or 5-FU combined with calcipotriene.

• Treatment field and size: Anatomic area and approximate surface area in square centimeters.

• Regimen and dates: Start date, stop date, frequency, and total duration.

• Adherence and tolerance: Completed course, partial course, or discontinued due to reaction.

• Response assessment date: The follow-up visit at which clearance was evaluated.

• Residual or recurrent lesion count: The number of lesions persisting or newly present in the treated field.

• Lesion morphology: Particularly hyperkeratotic or Olsen grade 2 to 3 lesions that resist topical penetration.

Define failure in objective terms. "Failed 5-FU" is a conclusion, not documentation. A defensible statement reads: "Completed fluorouracil 5% cream twice daily to bilateral dorsal hands for 4 weeks (dates). At 8-week reassessment, 11 hyperkeratotic AKs persist within the treated field." That sentence carries the agent, regimen, dates, assessment interval, residual count, and morphology in one line.

Intolerance is a valid failure category, but it requires specifics. Document the reaction (erosion, crusting, pain severity, secondary infection) and the date the patient stopped. Transplant patients sometimes discontinue early because erosive reactions on immunosuppressed skin heal slowly. That clinical reality supports lesion-directed treatment when documented.

Imiquimod requires a documented risk discussion in transplant recipients. Because it is an immune response modifier, many transplant dermatologists limit it to small fields and coordinate with the transplant team over theoretical graft rejection concerns. When imiquimod was avoided for this reason, document that decision; it explains why the field therapy history may involve only fluorouracil or photodynamic therapy.

Chemoprevention belongs in the plan. Oral nicotinamide, systemic retinoids such as acitretin, and discussion with the transplant team about converting to an mTOR inhibitor are standard considerations for SOTRs with high AK and SCC burden. Recording these discussions demonstrates longitudinal management and strengthens both medical necessity and any separately reported E/M service.

Standard: Agent, dates, interval, residual count. Four facts define failure.

Seven documentation parameters decide whether AK destruction claims survive audit

The table below maps each clinical parameter to its documentation requirement, the specific audit vulnerability it creates when missing, and the structured mechanism Scribing.io uses to capture it at the point of care.

Modifier 25 is supportable only when the E/M addresses problems beyond the destruction decision

CPT 17000 through 17004 carry a 10-day global period under the Medicare Physician Fee Schedule. That global surgical package includes the evaluation leading to the decision to perform the procedure. Examining an actinic keratosis and deciding to freeze it is part of 17000, not a separate E/M service.

Transplant patients frequently justify a separate E/M because their visits involve more than AK destruction. Legitimate separately identifiable work includes:

• Full-body skin cancer surveillance: Total body examination for cSCC, melanoma, and basal cell carcinoma in a high-risk patient, beyond the treated fields.

• Evaluation of a separate lesion: A new nodule, ulcer, or pigmented lesion requiring diagnostic decision-making.

• Chemoprevention management: Initiating, adjusting, or monitoring nicotinamide or acitretin, including lab review for retinoid therapy.

• Immunosuppression coordination: Documented communication with the transplant team about regimen modification based on skin cancer burden.

• Management of another dermatologic condition: For example, drug eruptions, infections, or warts common in immunosuppressed patients.

Structure the note in sections. The E/M portion should stand on its own if the procedure note were removed. Auditors increasingly test this by redacting procedure content and asking whether the remaining documentation supports the billed E/M level. If the residual E/M documentation discusses only the AKs that were destroyed, Modifier 25 will not survive.

Do not append G2211 to an E/M reported with Modifier 25 on the same date as a minor procedure. CMS policy permits G2211 with a Modifier 25 E/M only when the other same-day service is an annual wellness visit, vaccine administration, or a Medicare Part B preventive service. A 17000 series procedure does not qualify for that exception.

For a deeper analysis of Modifier 25 risk patterns and payer analytics, see Managing Modifier 25 Clinical Revenue Integrity.

Audit test: Remove the procedure note. Does the E/M stand alone?

Same-day PDT, biopsy, and destruction require lesion-level separation to avoid NCCI denials

Transplant patients often receive multiple premalignant and malignant lesion services on a single date. Each combination has a distinct bundling risk, and each must be resolved at the level of the individual lesion.

Photodynamic therapy and destruction on the same date

PDT codes 96573 and 96574 describe physician or QHP light application for premalignant lesions, with 96574 including debridement of hyperkeratotic lesions. 96567 describes PDT without direct physician or QHP involvement. Because 96574 already includes debridement, curettage of the same lesions cannot be billed separately as destruction. If a provider performs PDT on the face and cryosurgery on separate lesions of the dorsal hands, the destruction may be reportable, but the note must clearly identify separate anatomic sites and lesions. Modifier 59 or the more specific XS (separate structure) modifier applies only when the documentation supports distinct sites.

Biopsy and destruction on the same date

Biopsy and destruction of the same lesion during the same encounter cannot both be reported. When a provider biopsies a suspicious hyperkeratotic lesion on the left temple (11102 for tangential biopsy) and destroys twelve different AKs elsewhere, both services are reportable with XS appended appropriately and lesion locations documented for each. The biopsied lesion must not appear in the destruction count.

When pathology changes the code family

Hyperkeratotic AKs in transplant patients are frequently reclassified as squamous cell carcinoma in situ on histology. Destruction of a confirmed malignant lesion is reported with 17260 through 17286 (by site and diameter), not the 17000 series, and linked to the appropriate D04 or C44 diagnosis. If a lesion was destroyed as a clinical AK and later biopsy of a different lesion reveals SCC in situ, each lesion retains its own code family. Clinics should establish a hold rule so that encounters with pending pathology are not coded until the report returns.

Rule: Every lesion gets one site tag and one procedure.

Medical directors should run a monthly AK destruction audit against five failure points

High-volume 17004 billing in a transplant population is clinically appropriate, but it is also statistically conspicuous. Payer analytics compare your 17004 frequency, Modifier 25 attachment rate, and repeat destruction intervals against specialty peers. The medical director's role is to ensure the documentation matches the volume before an external reviewer tests it.

The five-point monthly audit

1. Count integrity: Pull 10 random 17000 series encounters per provider. Confirm that the site tally equals the billed units and that no ranges appear.

2. Code ladder accuracy: Run a claims report for any 17004 billed with 17000 or 17003, and any 17003 exceeding 13 units.

3. Diagnosis specificity: Verify that every transplant patient carries a Z94 status code and a fully specified Z79.6 subcode matching the medication list.

4. Field therapy timeline: For patients receiving 17004, confirm that a dated field therapy history or a documented reason for avoiding field therapy is present.

5. Modifier 25 separation: Apply the redaction test to every Modifier 25 encounter in the sample.

Operational roles that sustain compliance

• Providers own clinical content: Integer counts, morphology, failure definitions, and separately identifiable problems.

• Medical assistants own medication reconciliation: An updated immunosuppressive regimen before the provider enters the room.

• Coders own reconciliation: Count-to-unit verification and pathology hold rules before claim submission.

• The medical director owns feedback: Monthly provider scorecards with specific, quotable documentation gaps.

Key performance indicators to track

• Count-to-claim match rate: Target 100 percent; any mismatch is a corrective action item.

• Z79.6 specificity rate: Percentage of transplant encounters with a fully specified subcode.

• Field therapy documentation rate: Percentage of 17004 encounters with a complete failure timeline.

• Modifier 25 redaction pass rate: Percentage of sampled E/M services that stand alone.

• First-pass claim acceptance: Denials attributable to MUE, NCCI, or diagnosis specificity edits.

Standardize templates before you audit. Providers cannot meet a standard that their note structure does not prompt. The 1,000+ Specialty Clinical Macros library includes transplant dermatology AK destruction, field therapy follow-up, and high-risk skin surveillance templates that align with the five audit points above.

A defensible AK destruction note follows a fixed structure

The following structure gives providers and coders a shared format. Each element maps to an audit point, and none can be left blank without a documented reason.

• Transplant and immunosuppression context: Organ, transplant date, current agents and doses, transplant center contact.

• Skin cancer history: Prior cSCC count, most recent excision or Mohs date, metastatic history if any.

• Field therapy history: Agent, concentration, field, dates, adherence, reassessment date, residual count.

• Indication for lesion-directed destruction: Persistent or hyperkeratotic lesions after field therapy, intolerance, or documented contraindication.

• Consent: Risks of hypopigmentation, blistering, scarring, delayed healing in immunosuppressed skin, and recurrence.

• Procedure by site: Site, integer count, modality, freeze time, cycles, and margin for each site.

• Reconciled total and code: "Total AKs destroyed: 23. CPT 17004 times 1."

• Separately identifiable assessment: Full-body exam findings, other lesions, chemoprevention, and transplant coordination.

• Plan and follow-up: Wound care, surveillance interval (often every 3 to 6 months for high-risk SOTRs), and next field therapy decision.

Notice the reconciled total line. It converts a narrative into a verifiable billing statement. An auditor reading "Total AKs destroyed: 23. CPT 17004 times 1." needs no inference. That single line eliminates the most common destruction audit finding.

Scribing.io structures AK destruction documentation at the point of care

Ambient documentation tools that produce free-text narrative struggle with destruction coding because the critical data (counts per site, dates of prior therapy, specific immunosuppressive agents) arrive scattered across a conversation. A provider may say "three on the left ear" early in the visit and "another two behind that ear" ten minutes later. Narrative summaries often collapse those into "several lesions on the left ear."

The Scribing.io documentation object model treats each clinical parameter as a structured object rather than a sentence. When a provider dictates lesion counts, the Lesion Ledger records each site and count as discrete entries, updates the running total, and preserves later additions to the same site. Before any code is suggested, the Count-to-Code Reconciler confirms that the total maps to a valid 17000, 17003, or 17004 combination.

Immunosuppression Context Capture reads the reconciled medication list and the dictated assessment together. When a provider mentions tacrolimus and mycophenolate, the system prompts for the corresponding Z79.6 subcodes and the organ-specific Z94 status. When transplant status is absent, it flags the gap before the note is signed.

The Field Therapy Timeline object pulls prior encounters to reconstruct agent, dates, and reassessment counts. If the provider says "she failed 5-FU last spring," the system surfaces the prior prescription record and asks for the residual lesion count at reassessment. The result is an objective failure statement rather than a conclusion.

The Modifier 25 Separation Engine sorts dictated content into procedure-related and independent problem sections. Full-body surveillance findings, chemoprevention decisions, and transplant team communication are routed to the E/M assessment. AK evaluation for treated lesions stays in the procedure note. The output is pre-structured to pass the redaction test.

Medical directors can review these structured objects across providers to run the five-point audit without manual chart abstraction. See how this works in practice through the Scribing.io Clinical Interface.

Principle: Structured objects survive audits; narrative summaries invite them.

Count, context, and timeline together make transplant AK destruction claims defensible

Every defensible 17000 series claim in an immunosuppressed transplant recipient rests on three pillars. The count must be an integer that reconciles to the billed units. The context must name the transplanted organ and each immunosuppressive agent with fully specified Z79.6 subcodes linked alongside L57.0. The timeline must show, with dates and residual counts, why field therapy did not achieve clearance or why it was clinically avoided.

Clinic medical directors who standardize these three pillars across providers convert high-volume 17004 billing from an audit target into a documented standard of care. The transplant population needs aggressive, repeated premalignant lesion management. The documentation simply has to prove it, encounter by encounter, lesion by lesion.